HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk.

Jeffrey S MorrisManal M HassanYe Emma ZohnerZeya WangLianchun XiaoAsif RashidAbedul HaqueReham Abdel-WahabYehia I MohamedKarri L BallardRobert A WolffBhawana GeorgeLiang LiGenevera AllenMichael WeylandtDonghui LiWenyi WangKanwal RaghavJames C YaoHesham M AminAhmed Omar Kaseb

Published in: Hepatology (Baltimore, Md.) (2021)

HepatoScore-14 augments existing HCC staging systems, dramatically refining patient prognostic assessments and therapeutic decision making and enrollment in clinical trials. The underlying strategy provides a global biological characterization of disease, and can be applied broadly to other disease settings and biological media.

Keyphrases

clinical trial
decision making
lymph node
case report
pet ct
open label
phase ii